Why the study?
Variants in RYR1 or CACNA1S genes are linked to malignant hyperthermia susceptibility, which can lead to life-threatening reactions to potent volatile anesthetic agents or succinylcholine.
This CPIC guideline provides therapeutic recommendations for managing patients with RYR1 or CACNA1S variants to prevent malignant hyperthermia when using volatile anesthetics or succinylcholine.
Answers are grounded in this paper and cite their sources.
Prompts avoidance of triggering anesthetics in variant carriers; extends CPIC guidelines to standardize MHS pharmacogenomics.
The identification in a patient of 1 of the 50 variants in the RYR1 or CACNA1S genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life-threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these RYR1 or CACNA1S variants (updates at https://cpicpgx.org/guidelines and www.pharmgkb.org).
No takes yet. Share an insight, caveat, or question.
Gonsalves et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: